Frequently Asked Questions
Parallel imported products are always the same as the original. The only difference is that Paranova markets products that might have been produced for another European country; hence there can be differences in names or other markings. Sometimes differences can occur regarding excipients, e.g. colouring agents. Moreover, we act under the same regulations and laws as any other pharmaceutical company, ensuring that you get the safest and most reliable treatment from our products.
Society has the most to gain from parallel trading. By bringing competition to the market, Paranova and its colleague companies have been able to keep prices on drugs down, providing direct savings for patients as well as the whole of society. Without parallel importation, the bill for pharmaceuticals would have been considerably higher.
No. We, like any other pharmaceutical company, must comply with a number of laws and regulations set up in order to make sure that all necessary documentation, production facilities, distribution and environmental aspects meet the highest of standards.
Parallel trade refers to the purchase of trademarked or patented goods in one country, and the subsequent export of those goods to another country.The practice of parallel importation is driven by price differences among markets. Paranova is constantly monitoring the European market for the opportunity to import pharmaceuticals from a market with lower prices than those available in any Paranova-based country. This ultimately results in lower costs to the patient as well as to society.
Thanks to articles 28 to 30 of the EC Treaty that establish the principle of free movement of goods, parallel trading became possible in the early 1990’s. These articles stipulate that no artificial barriers may restrict the free movement of goods within the EU, which should function as a single market much like a national state.
First of all, even though Europe could be considered as one giant market, national governments control the price of products in such a way that they sell for different prices in each country. Furthermore, since social security programs work differently in each country, pharmaceuticals are valued differently, which further adds to disparate pricing.